Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study

"There were no COVID-19 related deaths among the 188 SARS-CoV-2 positive patients treated with disulfiram, in contrast to 5–6 statistically expected deaths based on the untreated population (P = 0.03). Our epidemiological results suggest that disulfiram may contribute to the reduced incidence and severity of COVID-19. These results support carefully planned clinical trials to assess the potential therapeutic effects of disulfiram in COVID-19."


Also see Harvard Gazette coverage here.  Veterans who were taking disulfiram had a 34 percent lower incidence of SARS-CoV-2 infection than those who weren’t, according to a retrospective study.


Popular posts from this blog

Managing Patients Taking Xylazine-Adulterated Opioids in Emergency, Hospital, and Addiction Care Settings

Prescription Drug Misuse and Addiction: Compassionate Care for a Complex Problem

International Overdose Awareness Day, August 31